CD10 Antibody (F-4): sc-46656

CD10 Antibody (F-4) is a mouse monoclonal IgG1 kappa light chain antibody that detects CD10 protein of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and enzyme-linked immunosorbent assay (ELISA). CD10 (F-4) antibody is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. CD10, also known as common acute lymphoblastic leukemia antigen (CALLA) and neutral endopeptidase (NEP), is a type II integral membrane glycoprotein that plays a crucial role in regulating peptide levels in the extracellular environment. As a zinc metalloprotease, CD10 cleaves a variety of biologically active peptides, including Angiotensins I and II, which are vital for blood pressure regulation and fluid balance. CD10 expression is observed on early B and T lymphoid precursors, B blasts, certain granulocytes, bone marrow stromal cells, and specific epithelial cells, including some tumor cell lines. CD10′s significance as a marker for common acute lymphocytic leukemias and certain lymphomas underscores its importance in both diagnostic and therapeutic contexts. Anti-CD10 antibody (F-4) is an essential tool for researchers studying hematological malignancies and the role of peptide regulation in various physiological processes.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

CD10 Antibody (F-4) References:

1. Analysis of CD10+ hairy cell leukemia.  |  Jasionowski, TM., et al. 2003. Am J Clin Pathol. 120: 228-35. PMID: 12931553
2. Prognostic impact of CD10 expression in clinical outcome of invasive breast carcinoma.  |  Vo, TN., et al. 2015. Breast Cancer. 22: 117-28. PMID: 23575921
3. Immunohistochemical expression of CD10 in cutaneous basal and squamous cell carcinomas.  |  Shafaei, S., et al. 2015. Caspian J Intern Med. 6: 103-7. PMID: 26221509
4. CD10 Immunohistochemical Expression in Apocrine Lesions of the Breast.  |  Kővári, B., et al. 2015. Pathobiology. 82: 259-63. PMID: 26562027
5. Monoclonal antibodies against human leucocyte antigens. II. Antibodies against CD45 (T200), CD3 (T3), CD43, CD10 (CALLA), transferrin receptor (T9), a novel broadly expressed 18-kDa antigen (MEM-43) and a novel antigen of restricted expression (MEM-74).  |  Horejsí, V., et al. 1988. Folia Biol (Praha). 34: 23-34. PMID: 2968928
6. Evaluation of CD10 expression as a diagnostic marker for colorectal cancer.  |  Żurawski, J., et al. 2022. Gastroenterol Hepatol Bed Bench. 15: 24-31. PMID: 35611259
7. Clinicopathologic Features and Treatment of CD10-Positive Mantle Cell Lymphoma: A Case Report and Review of Literature.  |  Hino, C., et al. 2022. Pathol Oncol Res. 28: 1610588. PMID: 36091937
8. FAP, CD10, and GPR77-labeled CAFs cause neoadjuvant chemotherapy resistance by inducing EMT and CSC in gastric cancer.  |  Zhao, Z. and Zhu, Y. 2023. BMC Cancer. 23: 507. PMID: 37277751
9. The distribution of CD10 (NEP 24.11, CALLA) in humans and mice is similar in non-lymphoid organs but differs within the hematopoietic system: absence on murine T and B lymphoid progenitors.  |  Kalled, SL., et al. 1995. Eur J Immunol. 25: 677-87. PMID: 7705396
10. Neutral endopeptidase modulation of septic shock.  |  Lu, B., et al. 1995. J Exp Med. 181: 2271-5. PMID: 7760013
11. Hematopoietic differentiation antigens that are membrane-associated enzymes: cutting is the key!  |  Shipp, MA. and Look, AT. 1993. Blood. 82: 1052-70. PMID: 8102558
12. CD10 in acute leukemias. GEIL (Groupe d'Etude Immunologique des Leucémies).  |  Béné, MC. and Faure, GC. 1997. Haematologica. 82: 205-10. PMID: 9175328

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-CD10 Antibody (F-4) has 30 citations in a variety of scientific publications.

Primary antibodies like Anti-CD10 Antibody (F-4) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

CD10 Antibody (F-4) Specifications

Alternate Product Name: Neprilysin

Product Clone Name: F-4

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids: 230-550

Epitope Target: CD10

Epitope Species: human

Product Reactivity/Detection: CD10

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P), ELISA

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 30 citations in various scientific publications

Available Conjugates/Forms for CD10 Antibody (F-4): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin